Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM

Annenberg Center for Health Sciences
  • 0.0 (0)
  • Medizin

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Folgen

  1. 19.11.2024

    Wrap Up

    Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM

  2. 19.11.2024

    Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

    Author: Howard, JF, et al. Overview Provided by Nicolas Silvestri, MD

  3. 19.11.2024

    Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

    Author: Strober J, et al. Overview Provided by Nicolas Silvestri, MD

  4. 19.11.2024

    Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results

    Author: Nicolle M, et al. Overview Provided by Nicolas Silvestri, MD

  5. 19.11.2024

    Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

    Author: Habib AA, et al Overview Provided by Nicolas Silvestri, MD

  6. 19.11.2024

    Introduction

    Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM

  • 6 Folgen

Info

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Informationen